Skip to main content
    C

    Cingulate Inc (CING)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.75
    -0.55 (-12.79%)

    Market Cap: $62.53M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Cingulate Inc (CING) Financials: Revenue, Profit and Cash Flow

    Updated Nov 13, 2026. Financial statements from company filings, amounts in US dollars.

    Cingulate reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$22.45M, operating cash flow was -$17.25M and free cash flow was -$17.41M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$7.73M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $19.94M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Cost of revenue$540.89K$0$0$0$0$0$178.91K
    Gross profit-$540.89K$0$0$0$0$0-$178.91K
    Research and development$9.77M$9.45M$15.49M$9.00M$8.41M$5.09M$9.09M
    Operating income-$19.94M-$15.64M-$22.76M-$17.50M-$20.68M-$7.08M-$11.65M
    Net income-$22.45M-$15.55M-$23.53M-$17.68M-$20.71M-$7.18M-$11.55M
    EBITDA-$19.40M-$14.99M-$22.18M-$17.11M-$19.97M-$6.52M-$11.47M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$12.98B$0$0$0N/A
    Gross profit$0$0$0$419.06K$0$0$0-$160.30K$0$0$0N/A
    Operating income-$7.49M-$5.41M-$7.92M-$5.59M-$6.00M-$4.65M-$3.71M-$6.21M-$3.28M-$3.21M-$2.95M-$6.80M
    Net income-$7.73M-$5.87M-$9.31M-$6.27M-$7.34M-$4.98M-$3.85M-$6.13M-$4.13M-$3.21M-$2.97M-$6.93M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $7.45M by $3.51M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$15.07M$14.86M$3.49M$11.41M$22.89M$5.79M$5.28M
    Current assets$12.01M$12.66M$578.59K$7.87M$18.88M$1.79M$978.32K
    Cash and equivalents$10.95M$12.21M$52.42K$5.36M$16.49M$1.20M$418.47K
    Total liabilities$12.56M$7.41M$10.36M$7.52M$2.04M$4.50M$4.66M
    Short-term debt$6.30M$2.53M$3.00M$5.00M$0$500.33K$375.82K
    Long-term debt$1.15M$2.44M$0N/AN/AN/AN/A
    Shareholder equity$2.51M$7.46M-$6.87M$3.88M$20.84M$1.29M$615.88K
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$28.15M$33.07M$30.86M$15.07M$10.52M$13.47M$12.47M$14.86M$13.58M$5.13M$5.49MN/A
    Total liabilities$7.38M$9.60M$12.00M$12.56M$7.05M$7.96M$6.54M$7.41M$1.54M$2.04M$2.28MN/A
    Cash and equivalents$23.19M$28.40M$25.89M$10.95M$6.12M$8.90M$9.52M$12.21M$10.04M$380.93K$1.11MN/A
    Shareholder equity$20.77M$23.47M$18.86M$2.51M$3.47M$5.51M$5.93M$7.46M$12.04M$3.08M$3.22MN/A
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$17.25M-$18.45M-$15.03M-$15.88M-$10.43M-$6.81M-$9.53M
    Capital expenditures$162.14K$211.80K$224.10K$153.42K$814.74K$402.10K$1.02M
    Free cash flow-$17.41M-$18.66M-$15.26M-$16.04M-$11.25M-$7.21M-$10.55M
    Share repurchasesN/AN/AN/A$85.92K$0N/AN/A
    Investing cash flow-$162.00K-$211.80K-$224.10K-$152.65K-$814.74K-$384.17K$2.74M
    Financing cash flow$16.15M$30.82M$9.95M$4.90M$26.54M$7.97M$6.14M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$7.38M-$5.90M-$6.91M-$3.60M-$4.24M-$4.80M-$4.61M-$4.08M-$3.88M-$1.74M-$8.75M-$2.56M
    Capital expenditures$83.18K$67.08K$61.18K$156.21K$4$5.92K$0$198.46K$140.79K$72.63K$81.51K$186.96K
    Free cash flow-$7.47M-$5.97M-$6.97M-$3.75M-$4.24M-$4.80M-$4.61M-$4.28M-$4.02M-$1.81M-$8.83M-$2.75M
    Last 12 quarters

    Frequently Asked Questions About CING

    What is Cingulate's annual revenue?

    Cingulate reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Cingulate profitable?

    No. Cingulate reported net income of -$22.45M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does CING generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$17.25M minus capital expenditures of $162.14K produced free cash flow of -$17.41M.

    How much debt does Cingulate have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $1.15M, short-term debt of $6.30M and cash and equivalents of $10.95M.